Amphotericin B (Fungizone)

Amphotericin B, marketed under the brand name Fungizone among others, is a powerful polyene antifungal medication used to treat serious systemic fungal infections in cats. This medication has been a cornerstone of antifungal therapy for decades and remains one of the most effective treatments available for life-threatening mycoses in feline patients. While its use requires careful veterinary supervision due to its potential for serious side effects, amphotericin B is often the medication of choice when cats develop deep-seated fungal infections that cannot be adequately treated with other antifungal agents.

Amphotericin B works by binding to ergosterol, a crucial component of fungal cell membranes that is not present in mammalian cells. When the drug binds to ergosterol, it creates pores or channels in the fungal cell membrane, leading to leakage of essential cellular contents and ultimately causing fungal cell death. This mechanism makes amphotericin B fungicidal rather than merely fungistatic, meaning it actively kills fungal organisms rather than simply inhibiting their growth. The drug demonstrates broad-spectrum activity against many pathogenic fungi that affect cats, including Cryptococcus, Blastomyces, Histoplasma, Aspergillus, and various other organisms responsible for systemic mycoses.

Amphotericin B is primarily available as an injectable formulation designed for intravenous administration. The conventional formulation, amphotericin B deoxycholate, has been largely supplemented by lipid-based formulations including liposomal amphotericin B and amphotericin B lipid complex, which offer improved safety profiles with reduced kidney toxicity while maintaining antifungal efficacy. Treatment with amphotericin B typically requires hospitalization or frequent veterinary visits, as the medication must be administered slowly through an intravenous catheter with careful monitoring of the patient throughout the infusion process.

Due to its significant potential for adverse effects, particularly nephrotoxicity, amphotericin B is reserved for serious fungal infections where the benefits clearly outweigh the risks. Veterinary supervision is absolutely essential throughout the entire course of therapy, and regular monitoring of kidney function through blood work is mandatory. Despite its toxicity concerns, amphotericin B remains an invaluable tool in veterinary medicine for treating cats with severe, potentially fatal fungal diseases, and when used appropriately under professional guidance, it can be life-saving for feline patients suffering from systemic mycoses.

The primary indication for amphotericin B in cats is the treatment of serious systemic fungal infections that pose a significant threat to the animal's health or life. Cryptococcosis represents one of the most common indications for amphotericin B therapy in feline patients, particularly when the infection has disseminated beyond the nasal cavity to involve the central nervous system, eyes, or other organ systems. Cryptococcus neoformans and Cryptococcus gattii infections in cats can be devastating if left untreated, and amphotericin B provides rapid fungicidal activity that can be critical in controlling the infection during the early treatment phase.

Blastomycosis is another important indication for amphotericin B use in cats, although this infection is less common in felines than in dogs. When cats do develop blastomycosis, the infection can involve the lungs, skin, eyes, bones, and central nervous system. Amphotericin B is often used as initial therapy to rapidly reduce the fungal burden before transitioning to oral antifungal medications for long-term management. Similarly, histoplasmosis in cats, caused by Histoplasma capsulatum, may require amphotericin B therapy when the infection is severe or disseminated, particularly when pulmonary involvement is significant or when the gastrointestinal tract is affected.

Aspergillosis, while more commonly a localized sinonasal infection in cats, can occasionally become invasive or disseminated, particularly in immunocompromised patients. In these cases, amphotericin B may be employed as part of the treatment regimen. The drug is also used for treating other serious fungal infections including coccidioidomycosis, sporotrichosis with systemic involvement, and various opportunistic fungal infections that may occur in cats with compromised immune systems.

Veterinarians may choose amphotericin B when other antifungal medications have failed to control an infection or when the severity of the disease warrants aggressive initial therapy. The drug is particularly valuable in cases where rapid reduction of fungal burden is necessary to prevent further tissue damage or when central nervous system involvement requires a medication that can achieve adequate concentrations in the brain and cerebrospinal fluid. Additionally, amphotericin B may be selected for cats that cannot tolerate oral medications or when absorption of oral antifungals is questionable due to gastrointestinal disease.

The selection of amphotericin B over other antifungal options depends on multiple factors including the specific fungal organism involved, the severity and extent of infection, the overall health status of the cat, and the availability of alternative treatments. While newer azole antifungals have replaced amphotericin B as first-line therapy for many fungal infections, amphotericin B remains the gold standard for certain severe mycoses and continues to play a vital role in the antifungal armamentarium for treating seriously ill feline patients.

Dosing of amphotericin B in cats requires careful veterinary oversight and individualization based on the specific formulation used, the type and severity of infection, and the patient's overall health status and kidney function. The veterinarian will determine the appropriate dose based on the cat's weight and the specific clinical circumstances, and doses should never be adjusted by pet owners without professional guidance. Treatment protocols vary considerably depending on whether conventional amphotericin B deoxycholate or one of the lipid-based formulations is being used.

Conventional amphotericin B deoxycholate is typically administered at lower individual doses given multiple times per week until a cumulative target dose is reached. Treatment often begins with a test dose to assess the patient's tolerance, followed by gradually increasing doses as the cat demonstrates the ability to tolerate the medication. The total cumulative dose required depends on the type of infection being treated and the clinical response observed. Lipid formulations, including liposomal amphotericin B and amphotericin B lipid complex, allow for higher individual doses with reduced nephrotoxicity, potentially shortening the overall treatment duration.

Treatment duration with amphotericin B varies considerably depending on the infection being treated and the clinical response. Systemic fungal infections in cats often require weeks to months of total antifungal therapy, and amphotericin B may be used for the initial intensive phase before transitioning to oral azole antifungals for maintenance therapy. The veterinarian will monitor the cat's response to treatment through clinical assessment, laboratory testing, and sometimes imaging studies to determine when adequate treatment has been achieved.

Administration of amphotericin B requires intravenous access, typically through an indwelling catheter, and the medication must be infused slowly over an extended period, often several hours. Pretreatment with intravenous fluids is standard practice to help protect the kidneys from drug-induced damage, and many protocols also include administration of medications to reduce infusion-related reactions. The cat must be monitored closely throughout the infusion for signs of adverse reactions including fever, shaking, vomiting, or changes in heart rate or breathing.

If a scheduled treatment is missed, pet owners should contact their veterinarian for guidance rather than attempting to make up the dose on their own. The treatment schedule may need to be adjusted, but this decision must be made by the veterinary team based on the specific circumstances. Doubling doses or making other adjustments without professional guidance could significantly increase the risk of serious adverse effects.

Completing the full course of amphotericin B therapy as prescribed is essential for successfully treating systemic fungal infections. Stopping treatment prematurely can allow the infection to recrudesce and may contribute to the development of antifungal resistance. Even after the amphotericin B portion of therapy is complete, many cats will require continued treatment with oral antifungal medications for months to ensure complete eradication of the infection. Regular follow-up appointments and laboratory monitoring are crucial throughout and after the treatment period.

Amphotericin B is known for its significant potential to cause adverse effects, and understanding these risks is essential for cat owners whose pets require this medication. When dosed appropriately and with proper supportive care, many cats can tolerate amphotericin B therapy, but close monitoring is absolutely mandatory throughout treatment. The most serious concern with amphotericin B is nephrotoxicity, or kidney damage, which occurs to some degree in most patients receiving the conventional formulation.

Common side effects during amphotericin B infusion include fever, shaking or rigors, decreased appetite, nausea, and vomiting. These infusion-related reactions are often most pronounced during the first few treatments and may diminish as the cat continues therapy. Many treatment protocols include premedication with antihistamines, anti-nausea medications, or other drugs to minimize these reactions. Cats may also experience phlebitis or inflammation at the intravenous catheter site, which requires careful catheter management and may necessitate catheter replacement during extended treatment courses.

Nephrotoxicity remains the most significant and dose-limiting adverse effect of amphotericin B therapy. The drug causes constriction of blood vessels in the kidneys and direct damage to kidney tubular cells, leading to decreased kidney function that can range from mild and reversible to severe and permanent. Signs of kidney problems may include increased thirst and urination, decreased appetite, vomiting, weight loss, and lethargy. Regular monitoring of blood urea nitrogen, creatinine, and other kidney parameters is essential, and treatment may need to be temporarily halted or the protocol modified if significant kidney impairment develops.

Hypokalemia, or low potassium levels, is another common complication of amphotericin B therapy that can cause muscle weakness, cardiac arrhythmias, and other problems if not recognized and corrected. Cats receiving amphotericin B typically require regular monitoring of electrolyte levels and may need potassium supplementation during therapy. Other laboratory abnormalities that may occur include anemia, which can develop during extended treatment courses due to bone marrow suppression, and abnormalities in liver enzymes.

Serious allergic reactions to amphotericin B, while rare, can occur and may manifest as acute collapse, difficulty breathing, facial swelling, or hives. Any signs of severe allergic reaction during infusion require immediate veterinary attention. The lipid-based formulations of amphotericin B generally cause less nephrotoxicity and fewer infusion-related reactions than the conventional deoxycholate formulation, and these may be preferred when available, although they are typically more expensive. Cat owners should promptly report any concerning symptoms to their veterinarian, including changes in urination patterns, persistent vomiting, extreme lethargy, or any signs of distress during or after treatment.

Amphotericin B is contraindicated in cats with known hypersensitivity or previous severe allergic reactions to the medication or any of its formulation components. While true allergic reactions to amphotericin B are relatively uncommon, any cat that has experienced anaphylaxis or other serious hypersensitivity reactions during previous treatment should not receive the drug again. Cross-reactivity with other polyene antifungals is possible, and a history of reactions to related medications should be disclosed to the veterinarian.

Cats with pre-existing significant kidney disease require extremely careful evaluation before amphotericin B therapy is considered. The drug's inherent nephrotoxicity makes its use particularly risky in patients whose kidneys are already compromised, and the potential for causing irreversible kidney failure must be weighed against the severity of the fungal infection being treated. In some cases, the lipid-based formulations may be used with extra caution in cats with mild kidney impairment, but severe kidney disease is generally considered a contraindication to amphotericin B therapy. Liver disease also warrants caution, as altered drug metabolism and an increased susceptibility to hepatotoxicity may occur.

The use of amphotericin B in pregnant cats is contraindicated due to the potential for fetal harm and teratogenic effects. The drug crosses the placenta and could adversely affect developing kittens. Nursing cats should also not receive amphotericin B, as the drug is excreted in milk and could harm nursing kittens. If a serious fungal infection requires treatment in a pregnant or nursing cat, alternative approaches must be carefully considered by the veterinarian, and in some cases, early weaning may be recommended if the mother's condition requires amphotericin B therapy.

Cats that are severely debilitated, dehydrated, or in shock are poor candidates for amphotericin B therapy until their condition can be stabilized. The stress of intravenous infusion combined with the drug's adverse effects could prove fatal in critically unstable patients. Additionally, cats receiving other nephrotoxic medications may have an increased risk of severe kidney damage if amphotericin B is added to their treatment regimen. A complete medication history, including any supplements or over-the-counter products, should be provided to the veterinarian to identify potential contraindications and drug interactions before therapy begins.

Before starting amphotericin B therapy, it is crucial that the veterinarian be informed of all medications, supplements, and treatments the cat is currently receiving or has recently received. Drug interactions with amphotericin B can significantly increase the risk of serious adverse effects, particularly nephrotoxicity, and may also affect the efficacy of treatment. Even seemingly innocuous supplements or over-the-counter products could potentially interact with this potent antifungal medication.

The most clinically significant interactions involve other nephrotoxic drugs that can compound amphotericin B's inherent kidney-damaging effects. Aminoglycoside antibiotics such as gentamicin and amikacin, when combined with amphotericin B, substantially increase the risk of severe and potentially irreversible kidney damage. Nonsteroidal anti-inflammatory drugs, certain diuretics, and other nephrotoxic agents including cisplatin and cyclosporine should be avoided or used with extreme caution during amphotericin B therapy. If concurrent use of potentially nephrotoxic medications is unavoidable, enhanced monitoring of kidney function is essential.

Corticosteroids and other immunosuppressive medications can potentially interfere with the immune response needed to help clear fungal infections, although in some cases these drugs may be used concurrently to manage inflammation or other aspects of the disease process. The decision to combine immunosuppressive therapy with amphotericin B requires careful veterinary judgment based on the specific clinical situation. Digitalis glycosides, used in cats with certain heart conditions, may have enhanced toxicity when combined with amphotericin B due to the hypokalemia that commonly develops during antifungal treatment.

Amphotericin B can cause significant electrolyte disturbances, particularly hypokalemia, which may affect the action and toxicity of other medications. Potassium supplementation is often required during therapy, and the timing and dosing of other medications may need adjustment based on the cat's electrolyte status. Azole antifungals such as fluconazole or itraconazole are sometimes used in combination with or following amphotericin B therapy, and while this combination can be beneficial for treating certain infections, it requires careful coordination by the veterinary team.

Throughout amphotericin B therapy, regular monitoring through blood work and clinical assessment helps identify potential drug interactions and allows for appropriate adjustments to the treatment protocol. Cat owners should never add any new medications, supplements, or treatments without first consulting with the veterinarian managing the amphotericin B therapy. Prompt reporting of any new symptoms or changes in the cat's condition helps ensure that any interaction effects are identified and addressed quickly.

Amphotericin B therapy requires extensive precautions and carries significant warnings that cat owners must understand before treatment begins. This medication should only be administered by or under the direct supervision of a veterinarian experienced in its use, and cats receiving amphotericin B must be monitored closely throughout the treatment course. The potential for serious adverse effects, particularly kidney damage, necessitates a commitment to regular veterinary visits and laboratory monitoring that may extend over weeks or months.

Accurate measurement of the cat's weight is essential for calculating the appropriate dose, and this weight should be rechecked periodically during therapy as sick cats may experience fluctuations. The veterinary team will also assess the cat's hydration status before each treatment, as adequate hydration is critical for minimizing nephrotoxicity. Pre-treatment hydration with intravenous fluids is a standard component of most amphotericin B protocols and should not be omitted.

Breed-specific sensitivities to amphotericin B have not been extensively documented in cats, but individual variation in drug tolerance certainly exists. Some cats may prove more susceptible to adverse effects than others, regardless of breed. Persian and Himalayan cats, which have a higher incidence of polycystic kidney disease, may require additional kidney function screening before therapy. Any cat with a history of kidney problems or a breed predisposition to kidney disease should be evaluated carefully before amphotericin B is prescribed.

Human handlers should exercise appropriate precautions when around cats receiving amphotericin B treatment. While the risk of exposure from a treated animal is minimal, the medication itself should be handled carefully by veterinary staff preparing and administering doses. Pregnant women and immunocompromised individuals should minimize contact with the drug and should not handle any medication vials or infusion equipment.

During treatment, cat owners should monitor their pet for signs of adverse effects including changes in appetite, increased thirst or urination, vomiting, lethargy, or any unusual behavior. The veterinary team will schedule regular blood work to monitor kidney function, electrolytes, and other parameters, and these appointments must be kept as scheduled. Signs of improvement in the fungal infection, such as resolution of skin lesions, improved respiratory symptoms, or enhanced neurological function, should be noted and reported to the veterinarian.

Geriatric cats and those with chronic conditions such as diabetes, heart disease, or compromised immune function require additional monitoring during amphotericin B therapy. Kittens are rarely treated with this medication due to their immature organ function and greater susceptibility to adverse effects. The decision to use amphotericin B in any special population must be made carefully by the veterinarian after considering all alternatives and discussing the risks and benefits with the cat's owner.

Amphotericin B requires specific storage conditions to maintain its stability and effectiveness, and these requirements vary depending on the specific formulation. The conventional amphotericin B deoxycholate powder for injection should be stored at refrigerated temperatures, typically between 2 and 8 degrees Celsius (36 to 46 degrees Fahrenheit), and protected from light. Once reconstituted, the solution has limited stability and should be used within the timeframe specified by the manufacturer, with unused portions discarded appropriately. Lipid formulations of amphotericin B have their own specific storage requirements detailed in their prescribing information.

Since amphotericin B is administered intravenously in a clinical setting, cat owners will not typically be responsible for storing or handling the medication itself. However, it is important to understand that this is a specialized medication that requires proper pharmaceutical handling by trained personnel. The medication must be reconstituted and prepared under appropriate conditions to ensure sterility and accurate dosing. Any amphotericin B solutions should be inspected visually for particulate matter or discoloration before administration.

Safe handling of amphotericin B requires attention to standard precautions for injectable medications. Healthcare workers preparing the drug should use appropriate personal protective equipment, and any spills should be cleaned up promptly according to established protocols. Cat owners should not attempt to handle or administer this medication outside of a veterinary facility. All medication waste, including vials, syringes, tubing, and catheters used during administration, should be disposed of properly according to veterinary facility protocols and local regulations for pharmaceutical waste.

If for any reason a cat owner is given amphotericin B or related supplies to bring to appointments, these should be kept in their original packaging, transported carefully, and stored according to any instructions provided by the veterinary team. Any medications that appear discolored, cloudy, or otherwise abnormal should not be used and should be returned to the veterinary facility for proper disposal. Medication take-back programs or veterinary facility disposal services should be utilized for any unused or expired antifungal medications to ensure safe environmental disposal.

Amphotericin B has not been associated with specific breed-related toxicities in cats, and most feline patients of any breed can receive this medication when it is clinically indicated and proper monitoring is in place. However, certain breed-specific health considerations may influence the decision to use amphotericin B and the intensity of monitoring required during therapy. Understanding these factors helps ensure the safest possible treatment for individual patients.

Breeds with known predispositions to kidney disease warrant particular attention before and during amphotericin B therapy. Persian and Himalayan cats have an increased incidence of polycystic kidney disease, which can cause significant kidney impairment that may not be clinically apparent until stressed by nephrotoxic medications. Abyssinian and Siamese cats may have higher rates of amyloidosis, another condition affecting kidney function. Pre-treatment screening with thorough blood work and urinalysis is advisable for cats of these breeds, and more frequent monitoring during therapy may be indicated.

Size considerations are relevant for precise dosing of amphotericin B in cats. Smaller cat breeds and individuals require careful weight-based dose calculations to avoid overdosing, while larger cats must receive adequate doses to achieve therapeutic drug concentrations. Body condition score and any recent weight changes should be factored into dosing decisions. Cats with low body weight due to illness may need additional supportive care during therapy and may be more susceptible to adverse effects.

Age represents an important consideration regardless of breed. Kittens have immature kidney function and metabolic processes that make them more vulnerable to drug toxicity, and amphotericin B is rarely used in very young cats. Geriatric cats often have some degree of age-related kidney function decline, even in the absence of overt kidney disease, and require careful baseline assessment and enhanced monitoring during treatment. Senior cats may also have concurrent health conditions that complicate therapy with this potent medication. The veterinarian will consider the individual cat's age, breed characteristics, and overall health status when developing a treatment plan and monitoring protocol for amphotericin B therapy.

Several alternative antifungal medications may be considered for treating systemic fungal infections in cats, either as primary therapy or in combination with amphotericin B. The azole antifungals, particularly fluconazole and itraconazole, are frequently used for feline fungal infections and may serve as alternatives to amphotericin B for less severe infections or as follow-up therapy after initial treatment with amphotericin B. These oral medications are generally better tolerated than amphotericin B and can be administered by owners at home, making them more practical for long-term therapy.

Fluconazole offers excellent penetration into the central nervous system and is often the preferred azole for treating cryptococcal meningitis in cats after initial stabilization with amphotericin B. Itraconazole is effective against many of the same fungal organisms and may be preferred for certain infections such as sporotrichosis. Ketoconazole, an older azole antifungal, is used less frequently now due to its greater potential for side effects compared to newer agents. Posaconazole and voriconazole are newer azole antifungals that may be used in selected cases, although experience with these drugs in cats is more limited.

For cats that cannot tolerate amphotericin B or azole antifungals, or when these medications prove ineffective, other options may be considered. Flucytosine is sometimes used in combination with amphotericin B for cryptococcosis, as the combination may be more effective than either drug alone and may allow lower doses of amphotericin B to be used. Terbinafine, typically used for dermatophytosis, has some activity against certain systemic fungi and may be employed in specific situations.

The selection of antifungal therapy must be individualized based on the specific fungal organism involved, its susceptibility pattern, the location and severity of infection, and the patient's overall health status and ability to tolerate treatment. Combination therapy using amphotericin B with an azole antifungal is sometimes employed to achieve faster or more complete resolution of infection. Cat owners should never substitute one antifungal medication for another without veterinary guidance, as different drugs have different spectrums of activity, dosing requirements, and safety profiles. The veterinarian managing the cat's fungal infection is best positioned to recommend the most appropriate antifungal regimen for each individual patient.